Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 11
1977 5
1978 3
1979 7
1980 7
1981 11
1982 15
1983 11
1984 16
1985 22
1986 21
1987 17
1988 18
1989 24
1990 25
1991 21
1992 26
1993 35
1994 19
1995 36
1996 21
1997 34
1998 32
1999 29
2000 28
2001 28
2002 27
2003 32
2004 31
2005 26
2006 43
2007 38
2008 48
2009 54
2010 54
2011 41
2012 38
2013 53
2014 48
2015 55
2016 48
2017 70
2018 60
2019 78
2020 68
2021 55
2022 47
2023 51
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

1,481 results

Results by year

Filters applied: . Clear all
Page 1
Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.
Kim PS, Fishman MA. Kim PS, et al. Curr Pain Headache Rep. 2020 Aug 26;24(10):64. doi: 10.1007/s11916-020-00898-0. Curr Pain Headache Rep. 2020. PMID: 32845365
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose naltrexone in the treatment of chronic pain. RECENT FINDINGS: Recent pre-clinical uses and clinical studies further elucidate the use o …
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose naltre …
The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.
Patten DK, Schultz BG, Berlau DJ. Patten DK, et al. Pharmacotherapy. 2018 Mar;38(3):382-389. doi: 10.1002/phar.2086. Epub 2018 Feb 23. Pharmacotherapy. 2018. PMID: 29377216 Review.
Naltrexone is a mu-opioid receptor antagonist indicated by the U.S. ...It is the purpose of this review to examine the evidence of the safety, tolerability, and efficacy of low-dose naltrexone for use in chronic pain and inflammatory conditions. Currently, ev …
Naltrexone is a mu-opioid receptor antagonist indicated by the U.S. ...It is the purpose of this review to examine the evidence of th …
Low-dose naltrexone as a treatment for chronic fatigue syndrome.
Bolton MJ, Chapman BP, Van Marwijk H. Bolton MJ, et al. BMJ Case Rep. 2020 Jan 6;13(1):e232502. doi: 10.1136/bcr-2019-232502. BMJ Case Rep. 2020. PMID: 31911410 Free PMC article.
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. ...Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with chronic f …
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. .. …
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Younger J, Parkitny L, McLain D. Younger J, et al. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Clin Rheumatol. 2014. PMID: 24526250 Free PMC article. Review.
We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone's bett …
We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells …
Is low-dose naltrexone effective in chronic pain management?
Radi R, Huang H, Rivera J, Lyon C, DeSanto K. Radi R, et al. J Fam Pract. 2023 Sep;72(7):320-321. doi: 10.12788/jfp.0654. J Fam Pract. 2023. PMID: 37729143 Clinical Trial.
YES. Low-dose naltrexone is as effective as amitriptyline in the treatment of painful diabetic neuropathy and has a superior safety profile (strength of recommendation [SOR], B; single randomized controlled trial [RCT]). Low-dose naltrexone significantly reduced pai …
YES. Low-dose naltrexone is as effective as amitriptyline in the treatment of painful diabetic neuropathy and has a superior safety p …
The Utilization of Low Dose Naltrexone for Chronic Pain.
Poliwoda S, Noss B, Truong GTD, Creech ZA, Koushik SS, Urits I, Viswanath O. Poliwoda S, et al. CNS Drugs. 2023 Aug;37(8):663-670. doi: 10.1007/s40263-023-01018-3. Epub 2023 Jul 28. CNS Drugs. 2023. PMID: 37505425
Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. ...Apart from these approved indications for the use of naltrexone, with time, it has been seen that this drug has a benefit in treating chronic pain. ...
Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. ...Apart from these approved indications …
Low Dose Naltrexone in the Treatment of Fibromyalgia.
Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Metyas S, et al. Curr Rheumatol Rev. 2018;14(2):177-180. doi: 10.2174/1573397113666170321120329. Curr Rheumatol Rev. 2018. PMID: 28325149 Clinical Trial.
BACKGROUND: ConclusionFibromyalgia is a chronic pain disorder characterized by diffuse musculoskeletal pain, fatigue, sleep disturbance and cognitive impairment. ...Thus, there is still a need for adjunctive therapies. METHOD: Naltrexone is an opioid receptor antago …
BACKGROUND: ConclusionFibromyalgia is a chronic pain disorder characterized by diffuse musculoskeletal pain, fatigue, sleep disturban …
Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review.
Hatfield E, Phillips K, Swidan S, Ashman L. Hatfield E, et al. J Am Dent Assoc. 2020 Dec;151(12):891-902.e1. doi: 10.1016/j.adaj.2020.08.019. J Am Dent Assoc. 2020. PMID: 33228882 Review.
BACKGROUND: The authors aimed to evaluate the efficacy of low-dose naltrexone in the management of chronic pain conditions and determine its potential use in orofacial pain management. ...The primary outcome of all of the studies was pain intensity reduction. CONCLU …
BACKGROUND: The authors aimed to evaluate the efficacy of low-dose naltrexone in the management of chronic pain conditions and …
Morphine/naltrexone.
Duggan ST, Scott LJ. Duggan ST, et al. CNS Drugs. 2010 Jun;24(6):527-38. doi: 10.2165/11204620-000000000-00000. CNS Drugs. 2010. PMID: 20443648 Review.
When morphine/naltrexone is taken as intended, naltrexone exerts no clinically significant effect. ...In a 12-month, open-label safety study, morphine/naltrexone also provided effective pain relief and sustained pain control in patients with chronic, m …
When morphine/naltrexone is taken as intended, naltrexone exerts no clinically significant effect. ...In a 12-month, open-labe …
Pilot Study of Low-dose Naltrexone for the Treatment of Chronic Pain Due to Arthritis: A Randomized, Double-blind, Placebo-controlled, Crossover Clinical Trial.
Beaudette-Zlatanova B, Lew RA, Otis JD, Branch-Elliman W, Bacorro E, Dubreuil M, Eyvazzadeh C, Kaur M, Lazzari AA, Libbey C, Monach PA. Beaudette-Zlatanova B, et al. Clin Ther. 2023 May;45(5):468-477. doi: 10.1016/j.clinthera.2023.03.013. Epub 2023 Apr 10. Clin Ther. 2023. PMID: 37045708 Clinical Trial.
PURPOSE: Low-dose naltrexone (LDN) is commonly used to control pain and other symptoms, especially in patients with autoimmune diseases, but with limited evidence. This study tests the efficacy of LDN in reducing chronic pain in patients with osteoarthritis (OA) and …
PURPOSE: Low-dose naltrexone (LDN) is commonly used to control pain and other symptoms, especially in patients with autoimmune diseas …
1,481 results

Searches related to "naltrexone chronic"